Bio-Rad Laboratories’ Post

💊Cancer drug resistance can be multifaceted which can be challenging to understand, model and target, making it an area of high unmet medical need. In our lunchtime seminar, our Executive Director of Integrated Solutions, Dr. Rajendra Kumari will outline the solutions available to reflect the clinical situation with the most effective preclinical tools, exploring both intrinsic and acquired resistance. Join us as we: ➡️Discuss the challenges of cancer drug resistance, the evolving landscape of clinical need, and how an integrated approach can be beneficial in early drug discovery ➡️Outline a four-step strategy to identify the most effective preclinical tools in response to the emergence of new resistance phenotypes, including both intrinsic and acquired from pretreated patients and the tools needed for deep characterization ➡️Provide examples of models with resistance to targeted therapy or immuno-therapeutics, describing the key features, challenges, and their applications Attendance is free and lunch will be served, but spaces are limited. We encourage you to register and reserve your seat early ➡️ https://hubs.la/Q02NMDg30 #Oncology #Bioscience

🔬 Don't miss out on an upcoming webinar showcasing ICON plc's experience with the TSO500 solid and liquid biopsy assay! As next-generation sequencing (NGS) becomes integral to cancer care, its role in refining drug development is evolving. Join us to explore the groundbreaking TruSight Oncology 500 (TSO500) assay, the only kitted comprehensive genomic profiling (CGP) assay submitted for pre-market approval (PMA) to the FDA. Discover how TSO500 sets the standard for reproducibility and accuracy across tissue types. Our expert speakers will delve into: ✅ Validation of TSO500 tissue ✅ Preliminary data on circulating tumor DNA (ctDNA) ✅ NGS application in oncology clinical trials REGISTER HERE: https://buff.ly/4bLzUZU 🌟 Featured speakers: Jin Li Jason Gottwals #PrecisionMedicine #NextGenerationSequencing #Oncology #Biomarkers #Genomics #LiquidBiopsy #NGS #ClinicalData #LaboratoryTechnology #BioanalyticalTesting #TumorBiomarkers

🎉 Exciting news from Illuminate Therapeutics! They have been awarded $275,000 by the National Science Foundation (NSF) for their groundbreaking work in cancer treatment. This award is part of the Small Business Innovation Research Program Phase I. #SBIR #STTR 💡 Illuminate Therapeutics is developing the LADDR platform for precise delivery of nucleic acid therapy for head and neck cancer and esophageal cancer. This innovative technology uses light-activated drug delivery to improve patient outcomes, targeting tumors while preserving healthy tissues. The project aims to identify predictive markers for responsive tumors and determine the pharmacokinetics and pharmacodynamics of the LADDR vehicle. #CancerResearch #Innovation 📅 The research will span 12 months, starting on September 1, 2024, and ending on August 31, 2025. This award reflects NSF's commitment to supporting impactful research with significant commercial potential. #NSF #HealthcareInnovation

Today on #WorldCancerResearchDay, we proudly stand with the global scientific community to underscore the critical role that research plays in improving cancer survival rates and enhancing the quality of life for patients and their families. At Zymeworks, we are deeply committed to the belief that continued research, innovation, and scientific advancement can profoundly impact the lives of cancer patients. As we advance our pipeline of multifunctional therapeutics, we honor our exceptional team of researchers, experts, and partners who are dedicated to harnessing the potential of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) to address high unmet needs in the treatment of difficult-to-treat cancers. Together, we are driving innovation within #cancerresearch and remain unwavering in our commitment to making a meaningful difference. #AntibodyDrugConjugates #MultifunctionalTherapeutics #Biotech #DrugDevelopment #DrugDiscovery #CancerAwareness #Oncology #ResearchandDevelopment

Upcoming #precisionmedicine webinar! https://lnkd.in/etTW5iwm Precision medicine is revolutionizing oncology, offering targeted and personalized therapies for patients. On December 4th at 10 AM, join industry experts Dr. Nehal Lakhani (START Midwest), Dr. Kyriakos Papadopoulos (START San Antonio), Dr. Geraldine O'Sullivan-Coyne (START Dublin), and Dr. Michael Axelson (Lilly) as they explore the current landscape of precision medicine and what’s next for this field of research. Our speakers will discuss the limitations of current approaches, innovative strategies to tackle “undruggable” targets, and leveraging protein-protein interactions to develop novel therapies. They’ll dive into the role of RAS oncogenes in cancer, challenges in targeting KRAS, and advancements in inhibitors. Additionally, the session will explore the potential of PROTACs as next-generation therapies, their design, and the promising targets being pursued. Finally, they’ll provide insights into strategies for tumor-agnostic drug development and navigating the FDA accelerated approval pathway for precision oncology therapies. Register now: https://lnkd.in/etTW5iwm #PrecisionMedicine #OncologyResearch #ClinicalTrials #DrugDevelopment #Webinar

First data demonstrating the relevance to treatment outcome of inferring tumor PSMA expression from comprehensive epigenomic profiling of circulating tumor DNA 🧬 🩸were presented at #AACRLBx24 - data from a great collaboration with Jacob Berchuck 👇🏾👇🏾 https://lnkd.in/eavCN46U With 30+ medicines targeting PSMA in clinical development, the PET-PSMA market leader estimates that 200K+ scans will be performed annually 5 years from now (in the US alone) in order to guide therapeutic decisions. With this anticipated growth in the need for PET-PSMA scanning…and with more than 40 additional medicines in clinical development against another 20 or so cell surface targets beyond PSMA… it’s clear to us at Precede Biosciences that there will be a real need for a blood-based test to guide decision-making and ensure maximum reach and impact for this next wave of precision medicines. #precisionmedicine #oncology #liquidbiopsy🩸

I’m delighted to present our latest LSD1 inhibitor preclinical data at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics today. Our poster highlights how combining human primary samples as a disease-relevant model system with drug perturbation experiments (transcriptomics, high-content imaging) can help identify novel PD biomarkers. Integrating multiple data levels with matched ex vivo sensitivity to '539 enhances the translational significance of these biomarkers, while preserving and understanding inter-patient variability in response to treatment with '539. In vivo experiments confirmed the upregulation of the biomarker candidates in response to '539 treatment, supporting the concept of introducing relevant model systems early in drug discovery to help provide clinically relevant preclinical data. If you’re attending ENA 2024, feel free to reach out or stop by PB238. #ENASymp24

Discovery is now offering tumoroids!  Introducing Tumoroid Cell Lines, OncoPro™ Medium-Derived. Also known as cancer organoids, tumoroids are patient-derived cancer cells grown as 3D, self-organized multicellular structures. They can be used for drug screening and testing, biomarker identification, drug response testing, drug dose and concentration studies, and more. These culture-ready tumoroid cell lines, alongside our matched biospecimens including DTCs, PBMCs, and FFPE tissue samples, enable oncology researchers to unlock deeper insights into tumor biology, understand disease mechanisms, and identify potential therapeutic targets.  Learn more: https://lnkd.in/gwZSSpFJ Discovery’s cell biology service lab also offers a suite of tumoroid add-on services that can generate physiologically relevant, multidimensional data.  Speak with our biospecimen specialist today:  https://lnkd.in/gE-9h74n #Tumoroids #CancerOrganoids #Oncology Note: OncoPro™ is a trademark of Thermo Fisher Scientific and its subsidiaries. These products are for research use only, not for use in diagnostic procedures.

For those #regulatoryaffairs folks who missed Pistoia Alliance's excellent round-table last week, you can watch it here: https://lnkd.in/eFFc78ch. It was great to see the 'Regulatoria' work Jean-Pierre Doan and team are spearheading at Merck Group; listen to some very interesting discussion among industry veterans Rita Algorri, Colin Wood, and see the work from the In Vitro Pharmacology Working Group (a novel public-private partnership between the FDA and Pistoia Alliance). We at Datum are working on a product to structure, streamline, and fast-track regulatory approvals for non-small cell lung cancer immunotherapies and would love to hear from pharma colleagues who are interested in learning more. Please register your interest here: https://lnkd.in/eNM3wGbw. #NSCLC #immunotherapy #cancer #oncology #regulatoryaffairs #regulatorysubmissions

Results from the GARNER study have just been published in Clinical Cancer Research. The GARNER study is the largest high-risk non-muscle invasive bladder cancer patient cohort ever assembled with both clinical and genomic detail. Recognizing that DNA alterations may not fully identify all patients who could potentially benefit from FGFR-targeted therapy, the study utilized GeneCentric’s RNA-based FGFR Predictive Response Signature (FGFR-PRS), which identified over twice as many patients with an activated FGFR pathway compared to patients with FGFR DNA alteration biomarkers. Read more at https://bit.ly/3BoqqqL #oncology #precisionmedicine #biotechnology #pharmaceuticals #RNAseq